FiteBac’s K21 is positioned to complete ovine sepsis recovery model and positioned for topical applications for wound & burn care with FDA CDER with PIND. FiteBac Pharma has pending joint Type-B meeting with CDER (for treatment of sepsis) and CVM (for animal growth and disease treatment). This meeting is to discuss K21 lack of pharmacokinetics where K21’s simple structure appears to be recycled in the cell with no detectable metabolites. Expansive pharmacogenomics will be presented prior to meeting as Breakthrough Therapy.